executive team
William DeVaul, JD
General Counsel and Secretary
William DeVaul is General Counsel and Secretary at Morphic Therapeutic. Bill brings more than two decades of experience as an attorney for public and private biopharma companies. Most recently, as Evelo Biosciences attorney, Bill was responsible for Evelo’s legal activities and intellectual property development and helped Evelo through an initial public offering in May 2018. Prior to Evelo, he represented Cubist Pharmaceuticals for 11 years up to its acquisition by Merck for $10B. Among his responsibilities as an attorney at Cubist, Bill led numerous licensing and collaboration deals, including public company acquisitions. Prior to Cubist, Bill practiced as an attorney at law firms in Boston and New York. Bill earned a law degree from Boston University School of Law and an undergraduate degree in Biochemistry from Columbia University.
Back to Executive Team
Scroll to Top

Contact Us

Integrin Partnership: Janssen

Morphic entered a research partnership with Janssen in 2019 to discover inhibitors of undisclosed integrin targets. In 2021, this partnership was expanded to include an antibody activator of an integrin target, extending the application of Morphic’s knowledge of integrin biology into modalities beyond small molecules. The antibody activator program is the focus of our collaboration with Janssen today.

Undisclosed Targets

Morphic is leveraging the MInT Platform to discover therapeutically relevant small molecule inhibitors of targets across the integrin family to treat autoimmune diseases, cancer and fibrotic diseases.

Undisclosed Target for Pulmonary Arterial Hypertension

Morphic is deploying the MInT Platform to create small molecule inhibitors of an undisclosed integrin target for evaluation as a potential treatment for pulmonary arterial hypertension (PAH). PAH is a devastating, usually fatal disease characterized by elevated mean pressures in the pulmonary artery and associated with lung and heart dysfunction. Morphic’s PAH program is in preclinical development.

αvβ8

Morphic is developing small molecule inhibitors of the integrin αvβ8 through a combination immuno-oncology approach for the treatment of solid tumors as well as potential additional indications. αvβ8 is known to activate selective isoforms of TGF-β and Morphic has demonstrated that αvβ8 inhibition can potentiate immune checkpoint blockade and potentially drive responses in checkpoint refractory tumors. Morphic’s αvβ8 inhibitors are in preclinical development.

Next Gen α4β7 Inhibitors

Morphic is developing a family of next generation α4β7 small molecule inhibitors with enhanced attributes using the MInT Platform. These candidates have distinct chemical properties from our first-generation inhibitors with differentiated selectivity, potency, and pharmacokinetic profiles. Morphic’s next generation α4β7 inhibitors are currently in preclinical development.